Barcelona, Spain - Grifols (MCE:GRF, MCE:GRF.P, NASDAQ:GRFS), a global leader in plasma medicines with more than 110 years contributing to improve the health and well-being of people, today announced that Egypt's ambassador to Spain, His Excellency Youssef Mekkawy, toured the Grifols plant in Parets del Valles (Barcelona), where he took in the world-class engineering currently being applied to the new Grifols Egypt manufacturing site being built in his country.

During his institutional visit, his first to Grifols, he met with company executives including Thomas Glanzmann, Executive Chairman and CEO; Raimon Grifols, Chief Corporate Officer; Victor Grifols Deu, Chief Operating Officer, as well as Grifols board member Tomás Dagà. Present from Grifols Egypt were Dr. Magdy Amin, CEO; and Dr. Ahmed Serag, head of Strategy and Projects.

The ambassador reaffirmed his country's commitment to Grifols Egypt for Plasma Derivatives, a joint venture between Grifols and Egypt's National Services Projects Organization to develop a fully integrated plasma-supply infrastructure that ensures domestic and regional self-sufficiency in plasma-derived medicines.

On his tour of the Parets del Valles plant, he singled out the advanced automation of the operations and strict adherence to the highest international levels of quality and safety, characteristics that will also define the new Grifols Egypt manufacturing facilities under construction in the New Administrative Capital's medical city. Once completed at the end of 2025 and operational, the site will produce the Grifols Egypt plasma-derived products that Parets del Valles is manufacturing in the meantime. Last week Grifols Egypt announced it is about to deliver its first shipment of medicines - albumin - to local hospitals.

All plasma for Grifols Egypt treatments comes from Egyptian donors and a growing network of plasma centers in the country. Six are open, another four are expected to be running before year-end, and in 2024 a total of 20 centers will be accepting donations.

.

(C) 2023 M2 COMMUNICATIONS, source M2 PressWIRE